European Diabetes Care Drugs Market to Reach $56.7 Billion by 2035

European diabetes care drugs market was valued at $29.3 billion in 2025 and is projected to reach $56.7 billion by 2035, growing at a CAGR of 6.9% during the forecast period (2026–2035). The Europe diabetes drug market is witnessing sustained expansion, primarily driven by the increasing prevalence of diabetes across the region. According to the International Diabetes Federation, diabetes prevalence in Europe is estimated at 9.8%, representing approximately 66 million diagnosed cases. This figure is projected to rise by nearly 10% by 2050, indicating a growing disease burden. Europe accounts for the highest number of type 1 diabetes cases, estimated at 2.7 million. From this total, nearly 15% are reported among individuals below 20 years of age, amounting to around 419,000 cases. The rising incidence of both type 1 and type 2 diabetes continues to accelerate demand for effective drug therapies. In 2024, diabetes-related healthcare expenditure in the region was estimated at USD 193 billion. This expenditure represented nearly 19% of total global diabetes spending. Additionally, Europe ranks second in terms of average cost per diabetes case, estimated at USD 2,951. These factors collectively highlight the strong growth potential of the diabetes drug market in Europe.

Browse the full report description of “European Diabetes Care Drugs Market Size, Share & Trends Analysis Report by By Diabetes Type (Type 1 diabetes, Type 2 diabetes, Gestational diabetes, Prediabetes / prevention), By Drug Class (Insulins, Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP-4 inhibitors, SGLT2 inhibitors, Others), By Formulation & Route (Oral tablets, Subcutaneous injections, and Inhalable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/europe-diabetes-care-drugs-market

Competitive Landscape and Strategic Developments in the European Diabetes Care Drugs Market

The major companies operating in the European diabetes care drugs market include AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S and Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

• In February 2025, Biocon announced the UK launch of its generic liraglutide products for the treatment of type 2 diabetes and weight management, referencing Novo Nordisk’s Victoza® and Saxenda®. Marketed as Liraglutide Biocon (gVictoza®) and Biolide (gSaxenda®), these products became the first UK-approved generics of liraglutide, following earlier regulatory approvals in the UK and EU and reflecting increasing global competition in the liraglutide market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Diabetes Type
  • Drug Class
  • Formulation & Route
  • Distribution Channel
• Competitive Landscape - AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S and Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Candy Market Report Segment

By Diabetes Type

• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes
• Prediabetes

By Drug Class

• Insulins
• Biguanides
• Sulfonylureas
• Thiazolidinediones (TZDs)
• DPP-4 inhibitors
• SGLT2 inhibitors
• Others

By Formulation & Route

• Oral tablets
• Subcutaneous injections
• Inhalable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

European Candy Market Report Segment by Region

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-diabetes-care-drugs-market